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The geographical risk areas for tick-borne encephalitis 
(TBE) in Finland remained the same until the beginning 
of the 21st century, but a considerable geographical 
expansion has been observed in the past 10 years. In 
order to support public health measures, the present 
study describes the number of laboratory-confirmed 
TBE cases and laboratory tests conducted and the 
associated trends by hospital district, with a particular 
emphasis on the suspected geographical risk areas. 
An additional investigation was conducted on 1,957 
clinical serum samples throughout the country taken 
from patients with neurological symptoms to screen 
for undiagnosed TBE cases. This study identified new 
TBE foci in Finland, reflecting the spread of the disease 
into new areas. Even in the most endemic municipali-
ties, transmission of TBE to humans occurred in very 
specific and often small foci. The number of antibody 
tests for TBE virus more than doubled (an increase by 
105%) between 2007 and 2013. Analysis of the number 
of tests also revealed areas in which the awareness of 
clinicians may be suboptimal at present. However, it 
appears that underdiagnosis of neuroinvasive TBE is 
not common.
Introduction
Tick-borne encephalitis virus (TBEV) is a clinically 
important flavivirus causing encephalitic disease 
with thousands of cases annually in Europe [1]. There 
are three known subtypes of TBEV: European (Eur), 
Siberian (Sib) and Far-Eastern (FE). The European sub-
type is mainly carried by Ixodes ricinus ticks in central 
and north-eastern Europe, whereas the other two are 
mainly found in I. persulcatus ticks in an area reach-
ing from north-eastern Europe to the Russian Far East, 
China and Japan [2].
TBEV is maintained in nature by ticks and their hosts. 
Ticks serve both as a reservoir and as vector for the 
virus [3]. Persistence in small mammals may also 
contribute to maintenance [4,5]. Ixodes ticks are widely 
spread generalist ectoparasites [6]. However, circu-
lation of TBEV is dependent on the local vegetation, 
dynamics of the vertebrate and tick host populations 
and microclimatic conditions, leading to focal occur-
rence of TBEV within the distribution area of the host 
ticks [3].
Humans do not contribute to sustain the circulation 
of TBEV but can get infected as accidental hosts by 
a tick bite or through consumption of unpasteurised 
milk from infected ruminants, particularly goats [7]. 
Besides genetic host factors, the course and severity 
of the infection may depend on the virus subtype and 
strain. Of the three subtypes, TBEV-FE is the one that 
most frequently induces severe tick-borne encephalitis 
(TBE), and the reported fatality rate reaches 35% [7]. 
TBEV-Sib causes a mortality of 2–3% and has been 
associated with chronic forms of TBE [1]. A biphasic 
course of infection is considered characteristic for 
TBEV-Eur: After an average incubation period of eight 
days, the viraemic phase, lasting one to eight days, 
manifests with unspecific influenza-like symptoms 
or remains subclinical [7,8]. After an asymptomatic 
period, 20–30% of the patients present with a neuroin-
vasive disease [7]. Although mortality is low for TBEV-
Eur, less than 2% [1,9], neuronal degeneration and 
post-encephalitis syndrome occur in up to one third 
of the patients and can have sequelae that reduce the 
quality of life [8,9]. Effective vaccines are available to 
prevent TBE caused by any of the three subtypes [2,7].
In Europe, the laboratory diagnosis of acute TBE is 
based on specific IgG and IgM antibody detection 
from serum and/or cerebrospinal fluid (CSF) [10,11]. 
Vaccination and natural infection with other flavivi-
ruses produce cross-reactive antibodies, which should 
be taken into consideration in the interpretation of IgG 
test results.
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There is no official definition of a TBEV-endemic area in 
Finland. However, foci with repeated human cases are 
considered risk areas. Most of these areas have been 
visited by our research group for collection of ticks and 
rodents to confirm the presence of TBEV in ticks and/
or host animals and to analyse the TBEV strains and 
tick species present in the area. Evidence from the past 
decade suggests a TBEV prevalence of up to 2% in I. 
ricinus and I. persulcatus ticks in TBEV foci throughout 
Finland [12-15].
Finland, together with the Baltic countries and western 
Russia, lies in the zone where the two main host tick 
species mix [2]. The overall distribution of tick spe-
cies in Finland has only been investigated in restricted 
areas, most of which are endemic TBEV foci. I. ricinus 
is the main tick species found in southern and south-
western Finland, while I. persulcatus is present in the 
north-west coast and at the eastern border of the coun-
try [12-16]. The TBEV subtypes endemic in Finland are 
TBEV-Eur and TBEV-Sib [13,15,16]. Interestingly, TBEV-
Eur was recently found in I. persulcatus ticks in the 
northernmost known TBE focus, in Simo, Finland [14]. 
All three subtypes are found in Russia and have been 
reported in Estonia and Latvia [17-19].
The first cluster of encephalitis cases in Finland 
occurred in Kumlinge, Åland in the 1940s; TBE, then 
known locally as Kumlinge disease, was described in 
1956 [20] and TBEV was isolated in Kumlinge in 1959 
(isolate A52) [8]. The number and geographical distri-
bution of human TBE cases in Finland remained stable 
for many decades, but in the past 10 years, the disease 
has become more common and spread to new foci.
In the present study we analysed the development of 
the geographical distribution and the number of TBE 
cases in Finland notified to the National Infectious 
Diseases Register (NIDR) in the period from 1995 to 
2013. In order to further support public health meas-
ures, we also describe the number of laboratory-con-
firmed TBE cases and of conducted laboratory tests as 
well as the associated trends for each of the 21 Finnish 
hospital districts, with a particular emphasis on the 
suspected risk areas. In addition, we used clinical 
serum samples from patients with neurological infec-
tion to investigate to which extent TBE cases and foci 
may have occurred unnoticed in Finland.
Methods
Tick-borne encephalitis diagnostics, case 
definition, and reporting
TBE is a notifiable disease in Finland according to the 
Communicable Disease Act and Decree. Two diagnos-
tic laboratories located in Turku (University of Turku) 
and Helsinki (HUSLAB, Helsinki University Hospital), 
perform TBE diagnostics and report acute cases to 
the Finnish NIDR at the National Institute of Health 
and Welfare (NIHW). Laboratory-confirmed cases are 
registered by the hospital district of the treating hos-
pital and dated by the first TBE IgM-positive clinical 
sample. Cases have been registered since 1995 with 
information on the place of residence and since 2007, 
detailed information on place and date of infection, 
date of first symptoms and clinical features have been 
collected from medical records and, when possible, in 
interviews.
The results submitted by the diagnostic laboratories 
to the Finnish NIDR are reviewed annually by special-
ists representing NIHW and the reporting laboratories 
using medical reports of the patients. During the study 
period (since 2007), this evaluation usually took place 
during the first months of the following year. Only 
cases that fulfilled the criteria for acute TBE (described 
below) are considered as cases and left in the register. 
In this study, we compared the data in the NIDR before 
and after the annual evaluation.
In Finland, the case definition of acute TBE is based on 
disease-specific medical history and clinical findings, 
absence of previous exposure to other flaviviruses, 
and detection of TBEV-specific IgG and IgM antibod-
ies in serum and/or CSF. The criteria are consistent 
with the case definition from the European Centre for 
Disease Prevention and Control (ECDC) [21], but in 
addition, also cases with a mild clinical picture, with-
out inflammation in the central nervous system (CNS), 
are registered. Only the classification ‘confirmed’ is 
used in Finland.
The TBEV IgM and IgG tests used In Turku are enzyme 
immunoassays (EIA) (Virion/Serion FSME virus/TBE, 
Wuerzburg, Germany). In HUSLAB, TBEV IgM is tested by 
an in-house μ-capture IgM EIA and confirmed by a hae-
magglutination inhibition (HI) test (described below). 
In the present study, we used the laboratory-confirmed 
Figure 1
All tick-borne encephalitis cases reported in the National 
Infectious Diseases Register, by place of diagnosis, 
Finland, 1995–2013 (n = 478)
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data, the re-evaluated data from the NIDR and the data 
from the interviews conducted by the NIHW.
Screening for antibodies against tick-borne 
encephalitis virus in sera from patients with 
central nervous system infection
Clinical serum samples, collected throughout Finland 
from patients with a CNS infection with suspected 
viral origin, were screened to identify previously undi-
agnosed TBE cases (Research permit §32 HUSLAB, 
2013). Convenience sampling representing the season 
of tick activity (i.e. daily mean temperature ≥ 5°C, in 
southern Finland this is late April to end of October, in 
northern areas a shorter period) was conducted in a 
sampling frame of serum specimens from patients with 
a suspected neurological infection, retrieved in 1997, 
2005–07 and 2011–12 and representing different geo-
graphical areas in Finland.
The samples had at the time of collection been sent to 
HUSLAB for screening of IgG and IgM antibodies against 
a panel of agents potentially causing CNS infection, 
including human herpesvirus 6, herpes simplex virus 
1 and 2, varicella zoster virus and Mycoplasma pneu-
moniae, but not TBEV. We excluded samples without 
diagnostic finding for the agents listed above as well 
as samples from patients who already had a diagno-
sis of TBE following an independent request to study 
anti-TBEV antibodies. Altogether 1,957 specimens were 
selected for this investigation.
The samples from 2005 to 2007 and 2011 to 2012 were 
screened with a modified μ-capture IgM EIA decribed 
earlier [22], except than an anti-FSME monoclonal anti-
body (Mab) [23] and a peroxidase-conjugated donkey 
anti-mouse IgG antibody (Jackson immunoresearch, 
West Grove, United States) were used in place of a 
peroxidase-conjugated anti-TBEV-Mab. The specificity 
of positive IgM reactions was further confirmed with an 
in-house HI test [24]. These methods are in routine use 
in the diagnostic laboratory at present. Samples from 
1997 were screened with an IgM-EIA (Progen Biotechnik 
GmbH, Heidelberg, Germany) and with an in-house HI 
test [24], the methods in routine use in the diagnostic 
laboratory at that time. 
Data from diagnostic laboratories conducting 
tick-borne encephalitis virus serology in 
Finland 2007 to 2013
We surveyed the databases of the two diagnostic 
laboratories conducting TBEV serology in Finland, the 
University of Turku and HUSLAB, including the refer-
ral information and TBE diagnostic test results (ethi-
cal permit THL/402/5.05.00/2014). Each patient was 
included only once in the data analysis. The patients 
were grouped by hospital district. Information on 
sex and age was only available for patients tested in 
HUSLAB, which represented 57% of all diagnostic data. 
Each municipality or private healthcare provider in a 
hospital district can choose the laboratory to which 
they send the specimens for TBEV antibody testing. 
The proportion of specimens sent to HUSLAB or to the 
University of Turku by each hospital district varied (the 
proportion sent to HUSLAB varied between 2.4% and 
100%).
Results
Descriptive analysis of notified tick-borne 
encephalitis cases in Finland in 1995 to 2013
Altogether 478 acute TBE cases were reported to the 
NIDR in the period from 1995 to 2013 (annual average: 
25 cases; range: 5–43) (Figure 1). Of these, 196 were 
Figure 2
Cases of tick-borne encephalitis, by geographical place of 
infection, Finland, 2007–13 (n = 192)
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All 192 cases with adequate information of the place of infection in 
Finland are included in the figure. Data of some geographically 
continuous areas were combined as follows: Simo: Simo and 
Kemi; Helsinki: Helsinki and Sipoo archipelago; Lappeenranta: 
Lappeenranta, Imatra, Lemi and Joutseno; Kotka: Kotka and 
Hamina archipelagos; Kokkola: Kokkola and Kannus. The south-
western (SW) archipelago extends to Kemiö in the south-east, 
includes the archipelago of Uusikaupunki in the north and 
excludes Åland in the west. The x axis of the graphs represents 
the date in years from 2007 to 2013. The y axis represents the 
cases (min=1 case, e.g. Tampere, Kuhmoinen and Inkoo 2013; 
max=14 cases, e.g. Åland 2010)
The northern limit of distribution of Ixodes ricinus in the 1960s is 
marked with a dashed line.
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reported from the Åland islands, a highly endemic 
area in south-western Finland. After 2006, when the 
national immunisation programme started providing 
vaccination for the population of Åland (n = 28,666 in 
2013 [25]), the majority of infections occurred on the 
Finnish mainland (i.e. areas other than Åland) (Figure 
1), however, the incidence still remained highest on 
Åland.
Geographical distribution
Adequate data on the place of infection was available 
for 208 (92%) of the 226 cases reported between 2007 
and 2013 (Figure 2). Of the total 226 cases, 74 (33%) 
were female; the median age was 48 years for men 
(range: 1–85) and 50 years for women (range: 4–81). 
In comparison, the median age for men in 2013 in the 
whole population was 39 years and for women 43 years 
according to Statistics Finland (personal communica-
tion Niina Haataja, June 2014). The median age of 3,190 
patients tested for suspected acute TBEV infection was 
43 years (range: 0–91), of whom 50% were female.
Of the 208 TBEV cases for whom detailed information 
was available, the infection site of 192 cases was in 
Finland (Figure 2). 
Figure 2 shows recent, earlier unreported areas with 
human TBE cases in Finland, namely Raahe, Pyhäjoki, 
Maalahti, Kuopio, Outokumpu, Varkaus, Kitee, 
Hirvensalmi, Kuhmoinen, Kotka, Tampere and Espoo. 
In many of these areas, infections have remained spo-
radic (Figure 3), however, some of these areas emerged 
only in the last year of the study and the development 
cannot be assessed yet. 
Of the cases with the infection site in Finland, 129 (67%) 
acquired the infection in their place of residence or in a 
neighbouring municipality. In the highly endemic areas 
of Åland and the south-western archipelago, respec-
tively two thirds (46/67) and half of the cases (25/49) 
were local residents. In the Simo-Kemi region, 13 of 16 
infections were acquired by local residents, whereas 
the proportion was four of eight in Kotka, archipelago 
seven of nine in Kokkola and 15 of 16 in Lappeenranta. 
Infections among local residents predominated also in 
the rest of the endemic areas. Altogether 16 cases were 
acquired abroad, mainly in countries neighbouring 
Finland: 10 persons acquired their infection in Estonia, 
three in Sweden, and one each in Russia, Austria and 
Switzerland.
Seasonality
Acute TBE cases were reported from 20 April through 
19 November. At both the start and the ends of this 
period, cases were detected in the south-western 
region. In Åland, 37 of 65 cases were reported evenly 
distributed from June to August, while 17 of the 65 
cases were observed in September. In the south-
western archipelago, there was a small peak in the 
number of cases in July and August, corresponding to 
the holiday season. Note that cases among residents 
of Åland were registered by the date of the first TBEV-
positive sample, while the cases from other parts of 
Finland were reported by the first date of symptoms. 
In Åland and the south-western archipelago, infec-
tions in late autumn were particularly common in 2010, 
2011 and 2013. In the south-eastern endemic area of 
Lappeenranta, 16 cases were reported from May to 
October, nine of them in August and September, while 
in the northern parts of the country, most cases were 
reported in June, with only one case in August and 
none later. 
Diagnosis
The average time from first symptoms to test-positive 
laboratory specimen was 13.4 days (range: 0–68, 
Figure 3
Hospital districts with continuous or sporadic occurrence 
of tick-borne encephalitis, Finland, 2007–13 (n = 192)
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Figure 4
Diagnostic laboratory tests for the detection of acute tick-borne encephalitis (n = 5,619) vs diagnosed cases (n = 226), 
Finland 2007–13
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median: 13). From 2007 to 2013, 106 TBE patients 
(68%) had noticed a tick bite before developing clini-
cal TBE (75% of the 208 interviewed patients provided 
this information). The number of laboratory tests con-
ducted in each hospital district varied between five 
and 1,629 tests conducted per 100,000 inhabitants in 
total in the period from 2007 to 2013 (Figure 4, Table 
1). Åland had the largest number of cases (n = 67, 
Åland as geographical site of infection) and the larg-
est number of tests conducted per 100,000 inhabitants 
(1,629/100,000). Of the five hospital districts with most 
cases (Åland, Varsinais-Suomi, South Karelia, Länsi-
Pohja, and Helsinki and Uusimaa), the smallest ratio 
of tests conducted vs cases diagnosed 2007 to 2013 
was seen in Varsinais-Suomi and Länsi-Pohja (Figure 
4, Table 1). Of the areas with sporadic cases (between 
one and 10 cases altogether in the study period), the 
largest ratio of tests conducted vs cases detected was 
seen in North Savo, Vaasa, and Central Ostrobothnia 
(Table 1).
During the study period, three patients died with 
acute TBE (1.3% of all reported cases): a person in 
their 60s with a neuroinvasive TBE, a person in their 
70s with TBEV encephalitis and a person in their 80s 
with confirmed TBEV encephalitis. The latter patient 
had received only one dose of TBE vaccine three weeks 
before the infection.
Screening of clinical samples for antibodies to 
tick-borne encephalitis virus
Of the 1,957 clinical serum samples from patients who 
had an infection with CNS symptoms in summer or 
autumn of the studied years, but had not previously 
Hospital district Patients tested
Tests/100,000 
inhabitants a Cases
b Positive tests 
%
Cases by site of 
infectionc
Incidence/100,000 
average 1995–2014
1 Helsinki and Uusimaa 1,114 70 58 5.2 10 0.55
2 Åland 467 1,629 52 11.1 67 39.47
3 Varsinais-Suomi 872 184 36 4.1 49 0.85
4 South Karelia 297 225 16 5.4 16 1.46
5 Länsi-Pohja 86 134 13 15.1 15 1.24
6 Vaasa 471 279 10 2.1 5 0.38
7 Northern Ostrobothnia 139 34 10 7.2 4 0.17
8 Central Ostrobothnia 357 456 7 2.0 9 1.22
9 Pirkanmaa 175 34 4 2.3 2 0.14
10 Kymenlaakso 72 41 4 5.6 8 0.20
11 North Savo 721 290 4 0.6 3 0.23
12 Satakunta 167 74 2 1.2 0 0.18
13 North Karelia 84 50 3 3.6 3 0.12
14 Päijät-Häme 96 45 1 1.0 0 0.03
15 South Savo 36 34 1 2.8 1 0.15
16 Kanta-Häme 42 24 1 2.4 0 0.09
17 East Savo 37 83 1 2.7 0 0.17
18 Central Finland 42 17 1 2.4 0 0.04
19 Southern Ostrobothnia 17 9 1 5.9 0 0.03
20 Lapland 59 45 0 0.0 0 0.04
21 Kainuu 4 5 0 0.0 0 0
Private laboratories d 264 NA NA NA NA NA
All 5,619 102 255 4.5 192 0.53 
NA: not applicable; NIDR: National Infectious Diseases Register; NIHW: National Institute of Health and Welfare; TBE: tick-borne encephalitis.
Incidence data and the cases were provided by the NIHW in the NIDR [41]. Hospital districts are listed by case numbers reported in the NIDR in 
descending order. For a map of the hospital districts see Figure 3. 
a Number of inhabitants in the hospital district in 2013.
b TBE cases reported by the NIHW in the NIDR in 2007 to 2013, by hospital district of the treating unit.
c TBE infections in 2007 to 2013 that occurred in the geographical area of the hospital district.
d The sending unit is not known for the private laboratories, however, the positive cases are included in the register of NIHW by area of the 
laboratory. In our analysis, we only analysed the frequency of the positive samples in this set of samples.
Table 1
Diagnostic tests for the detection of acute tick-borne encephalitis, by hospital districts, Finland, 2007–13 (n = 5,619)
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been tested positive for anti-TBEV antibodies, five 
(0.3%) were positive in both serological tests and ful-
filled the diagnostic criteria of acute TBE (Table 2). Of 
these five cases, three were from the hospital district 
of Helsinki and Uusimaa, one from Åland and one from 
Kymenlaakso. 
Tick-borne encephalitis surveillance system in 
Finland
Positive TBE test results, mainly positive TBEV IgM 
EIA results, are reported automatically to the NIDR as 
diagnostic TBE findings by the clinical laboratories. For 
the period 2007 to 2013, the case re-evaluation proce-
dure at the NIHW resulted in a 12.4% decrease (range: 
0–30.7 per year) in the annual number of TBE cases 
(data not shown). In most cases, this was because no 
IgG or HI seroconversion could be shown and the posi-
tive IgM test result was most probably unspecific. 
Discussion
This study demonstrates that in the past eight years, 
human TBE cases have emerged in new areas in Finland. 
An increasing number of TBE cases have been reported 
particularly along the north-western coast and in the 
south-western archipelago. Case numbers in Finland 
peaked in the early 2000s, mainly because of a signifi-
cant increase in TBE cases reported in Åland. The TBE 
incidence on Åland reached a peak in 2002 with 100 
per 100,000 population. Awareness of the disease led 
to an increase in TBE immunisations and since 2006, 
the national vaccination programme has provided the 
vaccine for residents of Åland, where the vaccination 
coverage in 2012 was estimated at 70.7% [26,27]. 
While the number of TBE cases on Åland has been 
steadily decreasing, the overall incidence between 
2007 and 2013 was still higher than in other parts of 
Finland. Furthermore, there have been indications of 
vaccine failure infections in Finland during the recent 
years (data not shown), as also reported in Sweden 
[28]. Vaccine failures have so far been studied sys-
tematically only on Åland. Age and number of vaccina-
tion doses have been reported as the most important 
factors influencing the immunological response to vac-
cination [29].
Case numbers have decreased considerably also in 
some of the smaller TBE foci in Finland that have been 
known for decades. These include Kokkola and the 
island of Isosaari in Helsinki, where our research group 
detected the Siberian and European TBEV subtypes, 
respectively, in rodents in 2008 and 2009, indicating 
that TBEV is still endemic, even if human cases are 
rare or absent [4]. We can assume that the observed 
decrease in case numbers was mainly due to increased 
awareness and subsequent immunisation. However, 
fluctuation of TBEV prevalence in ticks, annual fluctua-
tions in host rodent and tick populations, virulence of 
the circulating virus strains [30], and the probability for 
tick co-feeding may also regulate the risk of acquiring 
TBEV infection.
TBEV is, at least currently, found in very local foci 
in Finland. Even if a municipality is recognised as 
an endemic area, the true risk for a TBEV infection 
is restricted to areas smaller than the municipality. 
Studied foci and the patient cases reported are con-
centrated, in addition to Åland, along the coastline of 
the Baltic Sea and of Lake Saimaa, the largest inland 
waterway in Finland. Typically the foci are surrounded 
by water and appear on islands or headlands. This may 
be due to the favourable microclimatic conditions, 
vegetation and a suitable structure of host mammal 
populations for TBEV and ticks. Also human expo-
sure to ticks by the water is emphasised. Åland, the 
south-western archipelago and the Kotka archipelago 
are common holiday destinations and summerhouses, 
characteristic of the Finnish people, are usually located 
by water. In 2013, there were 498,700 summerhouses 
in Finland (population 5,451,270) [31]. In the south-
western parts of the country, the highest density of 
summer houses overlaps with the areas where the TBE 
incidence peaks. The majority of the cases in Finland 
were recorded in the municipality of residence or in the 
neighbouring municipality. Still, even in those cases, 
the infections were often acquired at a summerhouse 
Year Period of samples collection Number of samples
New 
cases a Hospital district 
b Proportion 
%
All cases registered in 
that year (NIHW)
1997 1 August–31 October 383 1 Helsinki and Uusimaa 0.26 19
2005 15 May–31 August 409 0 No cases 0.00 16
2006 16 May–31 August 250 1 Åland 0.40 18
2007 20 June–23 August 221 0 No cases 0.00 20
2011 1 June–31 October 374 3 Helsinki and Uusimaa (2 cases), Kymenlaakso (1 case) 0.80 43
2012 1 June–31 October 320 0 No cases 0.00 39
NIHW: National Institute of Health and Welfare; TBEV: tick-borne encephalitis virus.
a Patients with no previous TBEV diagnosis.
b Hospital districts as presented in Figure 3.
Table 2
Patients with central nervous system infections with unknown aetiology, Finland, 1997–2012 (n = 1,957)
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located by the sea or a lake and only rarely at the per-
manent residence. The focal nature and the infection 
risk at the summerhouse should be considered when 
the immunisation policies are planned and the budget 
for the provided immunisations are allocated.
During the last two decades, TBE case numbers have 
been increasing in many European countries, espe-
cially in northern Europe and northern parts of Russia 
[1-3,33,34]. Climate change is one, not completely 
understood, factor in this development [2,35]. In 
Finland and the neighbouring countries Sweden and 
Russia, host tick species and TBEV endemic foci have 
moved to more northern latitudes. In addition, I. rici-
nus has become more abundant in Sweden [14,34,36], 
and I. ricinus is found at higher altitudes in the central 
European mountain area [37]. At the same time, it has 
been predicted that TBEV may become rare or that the 
seasonality of cases may change in the traditionally 
highly endemic areas in central Europe [3,38]. Besides 
climate, human behavioural factors such as land use, 
socioeconomic changes, increased awareness of the 
disease and changes in the healthcare system have an 
influence on reported TBE case numbers [3,39].
No recent systematic countrywide survey on the distri-
bution of TBEV and the host Ixodes ticks is available in 
Finland, although areas with known human infections 
have been investigated. The geographical distribution 
of TBEV in Finland was last surveyed in the 1960s by 
screening of anti-TBEV antibodies in cattle sera col-
lected throughout the country [40]. The northern limit 
of I. ricinus ticks was found at the latitude of Kokkola-
Joensuu [40] (indicated in Figure 2). In a survey of 106 
TBE patients between 1959 and 1987 the identified 
geographical sites of infection were Åland, the south-
western region of Finland, Kokkola, the Helsinki region 
and north-eastern Finland [8]. In the present study, 
TBE cases were detected beyond these regions, par-
ticularly more to the north at the west coast (i.e. in 
the Raahe, Pyhäjoki and Simo-Kemi regions, 64°5’ to 
65°7’ N). However, according to earlier unpublished 
results (personal communication: Markus Brummer-
Korvenkontio, March 2015), anti-TBEV antibodies were 
already detected (by HI test and neutralisation) twice, 
two years apart, in a single cow in the 1960s in Tervola, 
a municipality next to Simo, suggesting that TBEV may 
have been endemic in the area already 50 years ago, 
even if no human cases were noted. The foci of Raahe 
and Pyhäjoki, as well as those in the inland lake region 
described here have not been reported previously.
I. persulcatus ticks are found on the north-west coast, 
overlapping, at least in Simo and in North Karelia, with 
emerging foci; at least in the Simo-Kemi region the ticks 
are carrying TBEV [13-16]. In south-western endemic 
areas, where I. ricinus is carrying TBEV, human cases 
were reported in the period between 20 April and 19 
November. The course of TBEV infection suggests that 
tick exposure occurred a few days to three weeks ear-
lier. In the northern regions, where I. persulcatus ticks 
are present, no autumnal cases were recorded. This 
may be due to different behaviour of the tick species or 
because the vegetation period is shorter in the north-
ern parts of the country.
The number of samples sent to diagnostic laboratories 
for TBE testing in Finland increased by 105% during the 
study period. However, the number of samples sent 
for TBE diagnostic tests did not in all hospital districts 
correlate with the TBE incidence. Awareness of TBE in 
northern parts of the country has increased since the 
first cases reported in Simo in 2008, but the number 
of tests conducted is still moderate. The district of 
Helsinki and Uusimaa stood out with a high number 
of tested samples, even if only a few infections were 
acquired in this area. TBE cases connected to travel 
in Finland or abroad or to a summerhouse in Finland 
were characteristic for the capital region. The observed 
increase in the number of infections with Parainen 
(south-western archipelago) as the geographical 
place of infection is reflected in the number of cases 
registered in Helsinki and Uusimaa. The third highest 
number of diagnostic samples was from North Savo, 
although only three sporadic human cases are known 
from this region (in Kuopio and Varkaus). Comparing 
the number of tests conducted with the number of 
cases diagnosed, the ratio was particularly low for 
Varsinais-Suomi and Länsi-Pohja, suggesting potential 
lack of awareness among clinicians for TBE in these 
known endemic areas.
We screened 1,957 patients for anti-TBEV antibodies. 
Patients had CNS infection of suspected viral origin 
but no previous TBEV suspicion or diagnosis. Five of 
them (0.25%) were found positive. We conclude that 
undiagnosed TBE forms only a minor fraction of this 
particular patient group. In addition, it is evident that 
the TBEV surveillance system in Finland, i.e. reporting 
the cases by laboratory results even if the clinical case 
definition is not fulfilled, is not sufficiently specific to 
avoid false positive reporting. As the Finnish NIDR is 
publicly available online, registering TBE cases with-
out full laboratory support (i.e. unspecific results) may 
raise unnecessary public concern in certain areas.
Conclusion
The overall TBE incidence in Finland is increasing and 
the virus is emerging in new geographical locations. 
Based on the present study, we have the following rec-
ommendations on TBE surveillance and prevention: (i) 
surveillance should be based on cases that fulfil the 
case definition at the time when the data are depos-
ited and the data should be evaluated frequently; (ii) 
irrespective of the funding arrangements, vaccination 
programmes should be targeted to all people staying 
in TBE-endemic regions for several weeks between May 
and October, not only permanent residents; (iii) in cer-
tain areas with a higher risk of transmission, awareness 
among clinicians should be increased; (iv) geographi-
cal information of TBE foci should be more precise and 
up-to-date, and used to estimate the population at risk. 
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A comprehensive study of TBEV prevalence (TBEV RNA 
in ticks and antibodies in host mammals in Finland) 
and a survey of the distribution of the two tick species 
should be conducted.
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